Recent reporting by Bloomberg announced that Stallergenes Greer will discontinue Palforzia, the first FDA-approved oral immunotherapy (OIT) for peanut allergy. The company stated the decision is voluntary and not related to safety or efficacy.

As an allergist who treats food allergies daily — and who offers peanut oral immunotherapy using carefully measured peanut flour in my practice — I want to reassure families:

This is not the end of peanut allergy treatment.

—

What Palforzia Actually Did

Palforzia was approved in 2020 to help reduce the risk of severe reactions from accidental peanut exposure. It was not a cure. Patients still needed to avoid peanuts, carry epinephrine, and take daily doses to maintain protection.

It was originally developed by Aimmune and later owned by Nestlé before being sold to Stallergenes.

The treatment worked for many patients — but it required time, consistency, monitoring, and insurance navigation. Those real-world challenges likely played a role in its discontinuation.

—

Oral Immunotherapy Is Still Available

Importantly, peanut OIT itself is not going away.

In my office, I provide structured peanut oral immunotherapy using standardized peanut flour. This approach follows well-established protocols and allows careful, individualized dosing under medical supervision.

For the right patient, OIT can:

Increase protection against accidental exposures

Reduce anxiety around cross-contact

Improve overall quality of life

But it is not for everyone.

—

Who Is a Good Candidate for OIT?

A good candidate typically:

✔ Has confirmed peanut allergy
✔ Has well-controlled asthma
✔ Can commit to daily dosing
✔ Understands this reduces risk — it does not cure the allergy
✔ Can attend regular follow-ups

Families whose daily lives are heavily impacted by fear of accidental exposure often benefit most.

OIT may not be ideal for those who cannot commit to daily therapy or who prefer strict avoidance and feel comfortable with that plan.

This decision is always individualized and made together with a board-certified allergist.

—

The Bigger Picture

Palforzia’s discontinuation reflects business realities — not scientific failure.

Food allergy care continues to evolve. We now have more tools than ever, including oral immunotherapy, biologic medications, and prevention strategies in infants.
Peanut allergy remains serious — but it is no longer a diagnosis with only one strategy.

As an allergist, I see progress every day. For some families, avoidance is still the right choice. For others, peanut OIT — including peanut flour–based protocols like the one I offer — can provide meaningful protection and peace of mind.

The future of peanut allergy treatment is still moving forward.